CA2850291A1 - Multi-specific binding molecules targeting aberrant cells - Google Patents

Multi-specific binding molecules targeting aberrant cells Download PDF

Info

Publication number
CA2850291A1
CA2850291A1 CA2850291A CA2850291A CA2850291A1 CA 2850291 A1 CA2850291 A1 CA 2850291A1 CA 2850291 A CA2850291 A CA 2850291A CA 2850291 A CA2850291 A CA 2850291A CA 2850291 A1 CA2850291 A1 CA 2850291A1
Authority
CA
Canada
Prior art keywords
binding
molecules
proteinaceous
domains
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2850291A
Other languages
English (en)
French (fr)
Inventor
Ralph Alexander Willemsen (Deceased)
Johan Renes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
APO-T BV
Original Assignee
APO-T BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by APO-T BV filed Critical APO-T BV
Publication of CA2850291A1 publication Critical patent/CA2850291A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2850291A 2011-09-29 2012-09-26 Multi-specific binding molecules targeting aberrant cells Abandoned CA2850291A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161540920P 2011-09-29 2011-09-29
US61/540,920 2011-09-29
PCT/NL2012/050675 WO2013048243A1 (en) 2011-09-29 2012-09-26 Multi-specific binding molecules targeting aberrant cells

Publications (1)

Publication Number Publication Date
CA2850291A1 true CA2850291A1 (en) 2013-04-04

Family

ID=47018432

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2850291A Abandoned CA2850291A1 (en) 2011-09-29 2012-09-26 Multi-specific binding molecules targeting aberrant cells

Country Status (6)

Country Link
US (3) US11098115B2 (enExample)
EP (2) EP3388451A1 (enExample)
JP (3) JP2014530009A (enExample)
AU (3) AU2012316859A1 (enExample)
CA (1) CA2850291A1 (enExample)
WO (1) WO2013048243A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012091564A2 (en) * 2010-12-27 2012-07-05 Apo-T B.V. A cross-linking polypeptide that induces apoptosis
WO2013048243A1 (en) 2011-09-29 2013-04-04 Apo-T B.V. Multi-specific binding molecules targeting aberrant cells
EP2802356A1 (en) 2012-01-13 2014-11-19 Apo-T B.V. Aberrant cell-restricted immunoglobulins provided with a toxic moiety
WO2014003552A1 (en) * 2012-06-26 2014-01-03 Apo-T B.V. Binding molecules targeting pathogens
WO2016077720A1 (en) * 2014-11-14 2016-05-19 Protein One, Llc Binding agents and uses thereof
TWI603980B (zh) * 2015-09-01 2017-11-01 免疫功坊股份有限公司 用以治療病理性血栓的聯合接合物構型藥物
US20190031785A1 (en) * 2016-01-13 2019-01-31 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
CA3102254A1 (en) * 2018-06-04 2019-12-12 Apo-T B.V. Methods and means for attracting immune effector cells to tumor cells
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を予防するための方法および組成物
DE102019121007A1 (de) * 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
WO2021263221A1 (en) * 2020-06-26 2021-12-30 Novather, Inc. Binding modulator
JP2024504903A (ja) * 2021-01-29 2024-02-02 中外製薬株式会社 細胞死が観察される組織において特異的に作用する分子
US12435444B2 (en) 2021-03-09 2025-10-07 Cdr-Life Ag Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same
EP4304726A1 (en) 2021-03-09 2024-01-17 CDR-Life AG Mage-a4 peptide-mhc antigen binding proteins
KR20240004937A (ko) 2021-05-05 2024-01-11 이매틱스 바이오테크놀로지스 게엠베하 Bma031 항원 결합 폴리펩타이드
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
EP4587046A1 (en) 2022-09-14 2025-07-23 CDR-Life AG Mage-a4 peptide dual t cell engagers
JP2025534663A (ja) * 2022-10-14 2025-10-17 フラッグシップ パイオニアリング イノベーションズ セブン，エルエルシー 治療薬の標的化送達のための組成物及び方法
CN119529098B (zh) * 2025-01-22 2025-05-30 北京可瑞生物科技有限公司 对mage-a1具有特异性的结合分子和抗cd3的融合蛋白

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB601513A (en) 1946-02-06 1948-05-06 Koray Ltd Improvements in or relating to coated tissue especially paper and to coating compositions therefor
DE321017C (enExample) 1917-05-15 1920-05-11 Aloysius Petrus Van Leuven
US3687370A (en) 1971-01-18 1972-08-29 Instapak Corp Liquid mixing and dispensing apparatus
NL9001639A (nl) 1990-07-19 1992-02-17 Amc Amsterdam Pt-houdende verbinding, werkwijze voor de bereiding ervan, alsmede toepassing van dergelijke verbindingen.
US5709995A (en) 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
NZ307633A (en) 1995-05-09 2000-01-28 Kreatech Biotechnology Bv Methods for the production of platinum-based linkers between labels and bio-organic molecules, for labelling bio-organic molecules, for detecting
EP0973785B1 (en) 1997-04-10 2003-12-03 Kreatech Biotechnology B.V. Trans-platinum compound, and diagnostic kit
PL196605B1 (pl) 1997-08-12 2008-01-31 Leadd Bv Sposób oznaczania zdolności transformującej, sposób oznaczania predyspozycji do przekształcania się w komórkę nowotworową, sposób oznaczania predyspozycji do dziedziczenia rodzajów raka, sposób oznaczania mutacji genu i diagnostyczny zestaw testowy
ID26964A (id) 1998-02-19 2001-02-22 Xcyte Therapies Inc Komposisi dan metode untuk pengaturan pengaktifan limfosit
EP1124568B1 (en) * 1998-10-21 2007-08-22 Altor BioScience Corporation Polyspecific binding molecules and uses thereof
IL127142A0 (en) 1998-11-19 1999-09-22 Yeda Res & Dev Immune cells having predefined biological specificity
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7527787B2 (en) 2005-10-19 2009-05-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
EP1377667B1 (en) 2001-03-30 2008-11-19 Leadd B.V. Fusion proteins for specific treatment of cancer and auto-immune diseases
CN1294148C (zh) 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 环状单链三特异抗体
JP4049297B2 (ja) 2001-06-11 2008-02-20 株式会社ルネサステクノロジ 半導体記憶装置
GB0115841D0 (en) 2001-06-28 2001-08-22 Medical Res Council Ligand
JP4303105B2 (ja) 2001-06-28 2009-07-29 ドマンティス リミテッド 二重特異性リガンドとその利用
US20100081792A1 (en) * 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
JP4213586B2 (ja) * 2001-09-13 2009-01-21 株式会社抗体研究所 ラクダ抗体ライブラリーの作製方法
EP1442301A1 (en) 2001-11-09 2004-08-04 Kreatech Biotechnology B.V. Means and methods for the detection of immunoglobulin capable of binding to mycobacterium antigen
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
AU2003216341A1 (en) 2002-02-20 2003-09-09 Dyax Corporation Mhc-peptide complex binding ligands
FR2837837B1 (fr) 2002-03-28 2006-09-29 Roussy Inst Gustave Epitopes peptidiques communs a des antigenes d'une meme famille multigenique
WO2003089467A1 (en) 2002-04-19 2003-10-30 Leadd B.V. Fragments of apoptin
CN1678634A (zh) 2002-06-28 2005-10-05 多曼蒂斯有限公司 免疫球蛋白单个变体抗原结合区及其特异性构建体
US7820166B2 (en) * 2002-10-11 2010-10-26 Micromet Ag Potent T cell modulating molecules
JP2006523437A (ja) 2002-12-03 2006-10-19 アヴィデックス リミテッド レセプター複合体
CA2519528C (en) * 2003-03-19 2016-01-26 Abgenix, Inc. Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof
AU2004242846A1 (en) * 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders
AU2004242845B2 (en) * 2003-05-31 2011-06-02 Amgen Research (Munich) Gmbh Human-anti-human CD3 binding molecules
US20050026881A1 (en) 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-IgE antibody for treatment of asthma or chronic obstructive pulmonary disease
ES2296423B1 (es) * 2003-07-31 2009-03-16 Consejo Sup. Investig. Cientificas Construccion de adn para la produccion de proteinas de fusion dimericas y sus aplicaciones.
US7488793B2 (en) * 2003-09-22 2009-02-10 Ludwig Institute For Cancer Research Isolated peptide which binds to HLA-Cw*07 and uses thereof
NZ576411A (en) 2003-11-17 2010-04-30 Genentech Inc Compositions and methods for the treatment of tumor of hematopoietic origin
PT2418220T (pt) 2003-12-10 2017-10-04 Squibb & Sons Llc Anticorpos contra interferão alfa e suas utilizações
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
JP4658967B2 (ja) 2003-12-24 2011-03-23 ジェネンテック， インコーポレイテッド 造血系起源の腫瘍の治療のための組成物と方法
US20050266425A1 (en) * 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
WO2005113595A2 (en) 2004-05-19 2005-12-01 Avidex Ltd High affinity ny-eso t cell receptor
US20100062001A1 (en) 2004-06-09 2010-03-11 Technion Research & Development Antibodies for selective apoptosis of cells
EP1809669A2 (en) * 2004-10-01 2007-07-25 Avidex Ltd T-cell receptors containing a non-native disulfide interchain bond linked to therapeutic agents
EP1957115B8 (en) 2005-11-10 2014-03-05 Celldex Therapeutics, Inc. Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen
US20090208502A1 (en) 2005-12-20 2009-08-20 Ralph Alexander Willemsen Apoptosis-inducing protein complexes and therapeutic use thereof
JP2009521474A (ja) * 2005-12-21 2009-06-04 メディミューン，エルエルシー ＥｐｈＡ２ＢｉＴＥ分子およびその使用
GB0601513D0 (en) 2006-01-25 2006-03-08 Univ Erasmus Medical Ct Binding molecules 3
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
CA2682093A1 (en) 2007-03-29 2008-10-09 Technion Research & Development Foundation Ltd. Antibodies, methods and kits for diagnosing and treating melanoma
PL2155788T3 (pl) * 2007-04-03 2013-02-28 Amgen Res Munich Gmbh Swoiste międzygatunkowe bispecyficzne czynniki wiążące
CN101952312A (zh) * 2007-07-31 2011-01-19 米迪缪尼有限公司 多特异性表位结合蛋白及其应用
US8568717B2 (en) 2008-04-03 2013-10-29 Vib Vzw Single domain antibodies capable of modulating BACE activity
WO2009131435A1 (en) 2008-04-23 2009-10-29 Erasmus University Medical Center Rotterdam Linker containing bungarotoxin and a binding peptide
KR20110016959A (ko) 2008-06-03 2011-02-18 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
AU2009299794B2 (en) * 2008-10-01 2015-08-13 Amgen Research (Munich) Gmbh Cross-species-specific single domain bispecific single chain antibody
CN102282168A (zh) 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
CA2747644C (en) 2008-12-19 2023-01-24 Ablynx N.V. Method for generation of immunoglobulin sequences
GB0908613D0 (en) * 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
SG176219A1 (en) 2009-05-27 2011-12-29 Hoffmann La Roche Tri- or tetraspecific antibodies
GB0911566D0 (en) * 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
EP2504360B1 (en) * 2009-11-23 2018-08-15 Amgen Inc. Monomeric antibody fc
EP2504358B1 (en) 2009-11-24 2016-10-19 ChronTech Pharma AB T cell receptors specific for immunodominant ctl epitopes of hcv
WO2011085473A1 (en) 2010-01-13 2011-07-21 Linda Penn Treating cancer with statins and compounds having dipyridamole activity
US20120123218A1 (en) 2010-11-16 2012-05-17 JPWaVe BV Methods and means for clinical investigations
WO2012091564A2 (en) * 2010-12-27 2012-07-05 Apo-T B.V. A cross-linking polypeptide that induces apoptosis
DK2658872T3 (da) 2010-12-27 2020-10-12 Apo T B V Polypeptid, der binder aberrerende celler og inducerer apoptose
WO2013048243A1 (en) 2011-09-29 2013-04-04 Apo-T B.V. Multi-specific binding molecules targeting aberrant cells
EP2802356A1 (en) 2012-01-13 2014-11-19 Apo-T B.V. Aberrant cell-restricted immunoglobulins provided with a toxic moiety
WO2014003552A1 (en) 2012-06-26 2014-01-03 Apo-T B.V. Binding molecules targeting pathogens

Also Published As

Publication number Publication date
AU2012316859A1 (en) 2014-04-17
EP2760892A1 (en) 2014-08-06
JP2020058354A (ja) 2020-04-16
JP2018046811A (ja) 2018-03-29
US11098115B2 (en) 2021-08-24
WO2013048243A1 (en) 2013-04-04
US20140227273A1 (en) 2014-08-14
US20250115662A1 (en) 2025-04-10
JP2014530009A (ja) 2014-11-17
AU2017248425A1 (en) 2017-11-02
AU2020200888A1 (en) 2020-02-27
AU2017248425B2 (en) 2019-11-14
EP3388451A1 (en) 2018-10-17
US20210355209A1 (en) 2021-11-18

Similar Documents

Publication Publication Date Title
US20250115662A1 (en) Multi-specific binding molecules targeting aberrant cells
US20230348627A1 (en) Anti-4-1bb-anti-pd-l1 bispecific antibody, and pharmaceutical composition and use thereof
JP7010487B2 (ja) 抗コチニン抗体が連結したキメラ抗原受容体およびその使用
WO2019154349A1 (zh) 抗pd-1/抗vegf天然抗体结构样异源二聚体形式双特异抗体及其制备
CN111699201B (zh) 抗pd-1/抗her2天然抗体结构的异源二聚双特异性抗体及其制备方法
EP2658873B1 (en) A cross linking polypeptide comprising a tetrameric single chain antibody binding mhc-mage complex that induces apoptosis
EP2850106A2 (en) Bispecific scfv immunofusion (bif)
JP7822576B2 (ja) 抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体
CN112119094A (zh) 与淋巴细胞活化基因3特异性结合的单克隆抗体及其用途
KR20260044203A (ko) 인간 cd7을 표적화하는 항체 또는 이의 항원 결합 단편 및 이의 응용
KR20230154235A (ko) NKp46에 대한 항체 및 이의 적용
US20250326845A1 (en) Single-domain antibody targeting pd-1, derivative thereof and use thereof
JP2023549977A (ja) 抗メソテリンｓｃＦｖを含むキメリック抗原受容体及びその用途
EP4606823A1 (en) Synthetic t cell receptor antigen receptor specifically binding to lilrb4 and use thereof
EP4714975A1 (en) Antibody binding lilrb4 and cd3, and use thereof
US20250136695A1 (en) Development of novel pdl1 single-domain antibody
NZ739019A (en) Multi-specific binding molecules targeting aberrant cells
WO2026092292A1 (zh) 一种结合cll1的纳米抗体、抗原受体及其应用
HK40095753A (en) Antibodies binding bcma and cd3 and uses thereof
JP2025528087A (ja) 二量体化可能な腫瘍抗原及び免疫刺激抗原を標的とする多重特異性抗体
Marshall Towards cancer immunotherapy

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170705

FZDE Discontinued

Effective date: 20220209